Related Experiment Videos
Intercellular adhesion molecule-1 release from human hepatocellular carcinoma
1Department of Internal Medicine, National Shikoku Cancer Center Hospital, Ehime, Japan.
Cancer Detection and Prevention
|January 1, 1996
Summary
Serum levels of adhesion molecules like E-selectin, VCAM-1, and ICAM-1 are elevated in liver disease patients. In hepatocellular carcinoma, elevated ICAM-1 is linked to tumor shedding, not just inflammation.
Area of Science:
- Immunology
- Hepatology
- Oncology
Background:
- Circulating adhesion molecules, including E-selectin, VCAM-1, and ICAM-1, play roles in inflammatory and cellular processes.
- Elevated levels of these molecules have been observed in various liver diseases, but their specific contributions in hepatocellular carcinoma (HCC) require further elucidation.
Purpose of the Study:
- To investigate and compare serum levels of E-selectin, VCAM-1, and ICAM-1 in patients with chronic hepatitis (CH), liver cirrhosis (LC), and HCC.
- To determine the relationship between these adhesion molecules and disease severity, particularly in HCC, and to assess the contribution of tumor shedding to circulating ICAM-1 levels.
Main Methods:
- Enzyme-linked immunosorbent assays (ELISA) were used to quantify serum levels of E-selectin, VCAM-1, and ICAM-1 in 38 CH, 29 LC, and 43 HCC patients, compared to 40 healthy controls.
- Immunohistochemistry was employed to evaluate the in situ expression of these adhesion molecules in 10 HCC tissue samples.
- Statistical analyses were performed to assess correlations between adhesion molecule levels, disease status, and tumor characteristics.
Main Results:
- All patient groups (CH, LC, HCC) exhibited significantly higher serum levels of E-selectin, VCAM-1, and ICAM-1 compared to normal controls.
- Serum VCAM-1 and ICAM-1 levels were correlated in CH and LC patients, but this correlation diminished in HCC patients, especially with larger tumors.
- While actual serum ICAM-1 levels did not correlate with tumor size, predicted ICAM-1 shedding from tumor cells showed a strong correlation with tumor size in HCC patients.
- Immunohistochemistry revealed enhanced ICAM-1 expression on HCC tumor cells, with no significant expression of E-selectin or VCAM-1.
Conclusions:
- Elevated serum adhesion molecules in HCC patients are primarily driven by underlying liver inflammation, similar to CH and LC.
- Tumor cells in HCC contribute to elevated serum ICAM-1 levels through shedding, and this shedding is proportional to tumor size.
- While inflammation is the main driver, tumor-derived ICAM-1 shedding represents a specific biomarker for HCC progression.